贝那普利联合来氟米特治疗IgA肾病的疗效

目的观察贝那普利联合来氟米特治疗IgA肾病的临床疗效。方法 60例IgA肾病患者随机分为两组:治疗组30例,给予贝那普利10mg/d联合来氟米特20mg/d;对照组30例,单用贝那普利10mg/d。疗程均为6个月。比较两组临床疗效。结果治疗组总有效率为83.3%(25/30),明显高于对照组的66.7%(20/30)(P<0.05)。治疗组治疗后尿蛋白定量为(0.62±0.24)g/24h,低于对照组的(1.62±0.46)g/24h,血清白蛋白为(40.36±10.32)g/L,高于对照组的(32.86±10.31)g/L(P<0.05)。结论贝那普利联合来氟米特治疗IgA肾病能提高患者血清白蛋白水平,减少蛋白尿。

Efficacy of benazepril combined with leflunomide in treatment of IgA nephropathy

Objective To investigate the clinical efficacy of benazepril combined with leflunomide in treating IgA nephropathy.Methods Sixty patients with IgA nephropathy were equally randomized into two groups of A(treated with benazepril 10 mg/d combined with leflunomide 20 mg/d for 6 months) and B(treated with benazepril for 6 months).Clinical efficacy was compared between two groups.Results The total effectiveness rate of group A was 83.3%,which was higher than 66.7% of group B(P<0.05).After treatment,urine protein was lower in group A than that in group B(0.62±0.24) g/24 h vs.(1.62±0.46) g/24 h and serum albumin was higher in group A than that in group B(40.36±10.32) g/L vs.(32.86±10.31) g/L(P<0.05).Conclusion Benazepril combined with leflunomide can effectively increase serum albumin and reduce urine protein of patients with IgA nephropathy.